Selection of a multidrug-resistant Aeromonas during medicinal leech therapy
Case report published in New Microbes New Infect (2017)
Abstract
We report the selection in a 15-year-old boy of a multidrug-resistant, extended-spectrum β-lactamase (ESBL)-producing Aeromonas salmonicida after medicinal leech therapy that required an antibiotic prophylaxis based on piperacillin/tazobactam and cotrimoxazole. Whole genome sequencing of the strain indeed revealed 13 antibiotic resistance genes, including the ESBL CTX-M-3 and the unusual β-lactamase SCO-1.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
15-year-old boy developed ESBL-producing CTX-M-3 Aeromonas with 13 antibiotic resistance genes after piperacillin/tazobactam and cotrimoxazole prophylaxis during leech therapy.
Warum dies für die Hirudotherapie relevant ist
The abstract reports the selection of a multidrug-resistant, extended-spectrum β-lactamase-producing Aeromonas salmonicida strain in a 15-year-old boy after medicinal leech therapy; the case required antibiotic prophylaxis based on piperacillin/tazobactam and cotrimoxazole. Whole genome sequencing identified 13 antibiotic resistance genes, including the ESBL CTX-M-3 and the unusual β-lactamase SCO-1. This is directly relevant to ASH's domain as it documents a multidrug-resistant pathogen associated with leech therapy, a notable safety consideration. The limitation is that this describes a single case, and the abstract does not specify the leech indication, clinical outcome, or the temporal relationship between prophylaxis administration and the emergence of resistance.
Zitation
Selection of a multidrug-resistant Aeromonas during medicinal leech therapy.
Ruppe E et al. · New microbes and new infections, 2017
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026